The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
International Guidelines with a large Canadian presence in the committee
Claims & Support/References for Claims
1
Posts
1
Posters
16
Views
-
Hi! We are interested in using a set of International Guidelines to provide messages about its recommendations and to make place-in-therapy claims about our product. While we note that international guidelines are generally not accepted and that PAAB favours Canadian and American guidelines, over 10 of the authors on these guidelines (including the lead author) are Canadian. Furthermore, because these guidelines are for a rare disease, there is no Canadian authoritative medical body that focuses on the disease, so getting "endorsement" from such a body may be difficult. Given these circumstances, would PAAB be a bit more flexible regarding the use of these guidelines?